Immunovant, Inc. filed its quarterly report on Form 10-Q for the period ended September 30, 2026, disclosing a net loss of $250.470 million for the six months ended September 30, 2026, with cash and cash equivalents of $722.274 million as of that date.

Key Highlights

  • Net loss (six months): $250.470 million for the six months ended September 30, 2026, compared to $247.115 million for the same period in 2025.
  • Net loss (quarter): $97.246 million for the three months ended September 30, 2026, compared to $126.502 million for the three months ended September 30, 2025.
  • Cash position: Cash and cash equivalents stood at $722.274 million as of September 30, 2026, down from $902.110 million at March 31, 2026.
  • Research and development expenses (six months): $227.642 million, up from $215.449 million in the prior-year period.
  • Loss per share (six months): Basic and diluted net loss per common share of $1.22, compared to $1.43 for the six months ended September 30, 2025.
  • Shares outstanding: 206,785,540 shares of common stock issued and outstanding as of September 30, 2026, and 206,947,758 shares as of November 3, 2026.
  • Total stockholders' equity: $656.945 million as of September 30, 2026, down from $852.592 million at March 31, 2026.

Immunovant's Financial Results for the Quarter and Six Months Ended September 30, 2026

According to the filing, Immunovant reported total operating expenses of $104.155 million for the three months ended September 30, 2026, compared to $131.762 million in the same quarter of the prior year. For the six-month period, total operating expenses were $264.478 million, up from $258.986 million. Research and development accounted for $85.011 million of the quarterly operating expenses and $227.642 million for the six-month period. General and administrative expenses were $19.144 million for the quarter and $36.836 million for the six months ended September 30, 2026.

The company disclosed interest income, net, of $6.897 million for the three months ended September 30, 2026, and $13.992 million for the six-month period. No provision for income taxes was recorded for either period in fiscal 2027, compared to $594 thousand and $1.507 million, respectively, in the prior-year periods. The weighted-average common shares outstanding used for the basic and diluted loss-per-share calculation were 206,667,558 for the quarter and 206,143,035 for the six months ended September 30, 2026.

As reported on the balance sheet, total assets were $760.967 million at September 30, 2026, against $957.014 million at March 31, 2026. Total liabilities were $104.022 million at September 30, 2026. The accumulated deficit reached $1.995599 billion as of September 30, 2026, compared to $1.745129 billion at March 31, 2026. Stock-based compensation recorded during the three months ended September 30, 2026, was $12.895 million, and a capital contribution related to stock-based compensation of $386 thousand was also recorded in that quarter, according to the filing.

What Was Disclosed

Immunovant filed its Form 10-Q for the quarterly period ended September 30, 2026, reporting a six-month net loss of $250.470 million, cash of $722.274 million, accumulated deficit of $1.995599 billion, and total stockholders' equity of $656.945 million, with no revenue line reported in the statements of operations.